Keytruda Approved for Adjuvant Rx in Melanoma Patients With Lymph Node Involvement

The FDA approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) after complete resection.

“Not too long ago, there were limited treatment options for patients with advanced melanoma,” said Marc Hurlbert, PhD, the chief science officer at the Melanoma Research Alliance. “Today’s approval of [pembrolizumab] in the adjuvant setting provides melanoma patients with another option to prevent their cancer